Abstract. The majority of human solid tumors exhibit aneuploidy caused by impairment of the mitotic checkpoint. Since the Mad2, Bubr1 and aurora kinase B (aurKB) proteins are involved in the mitotic checkpoint, we investigated Mad2, BubR1 and AURKB mrna expression and its effect on clinicopathological parameters and prognosis in 100 consecutive patients who underwent surgical resection for gastric cancer. Mad2, BubR1 and AURKB mrna expression levels in gastric cancer tissues and corresponding normal gastric mucosa were compared by real-time quantitative rT-Pcr. The data were then correlated to clinicopathological parameters and prognosis. The expression of Mad2, BubR1 and AURKB mrna was found to be significantly higher in cancer tissue compared to normal tissue. BubR1 and AURKB expression was significantly higher during the earlier stages of the disease. Patients with high BubR1 expression had improved relapse-free survival and overall survival compared to patients with low BubR1 expression. Multivariate analysis of stage ii and iii patients indicated that high expression of BubR1 and/or AURKB was associated with improved overall survival. We conclude that overexpression of BubR1 and AURKB is associated with a low risk of gastric cancer progression, and that overexpression of BubR1 and/or AURKB can therefore be used to identify gastric cancer patients with a favorable prognosis.
Introduction
despite the declining incidence of gastric cancer, the disease remains the fourth most common cancer and the second most frequent cause of cancer-related death worldwide (1, 2) . recent progress in diagnostic and treatment technologies has improved the long-term survival of patients with earlystage gastric cancer, although the prognosis for patients with advanced disease remains unfavorable (3) . Surgical treatment is the mainstay of therapy for patients with localized disease, but adjuvant chemotherapy is required after surgical resection in advanced cases (4) . Thus, the identification of prognostic factors may contribute to improved treatment strategies for gastric cancer patients. This requires further insight into carcinogenesis and cancer progression.
The majority of human solid tumors exhibit aneuploidy (5), which is a very early event in the progression of gastric cancer (6) . Tumor cells become aneuploid as a result of aberrant mitotic division, caused by a defective mitotic checkpoint response. The mitotic checkpoint is a signaling cascade that arrests the cell cycle in mitosis when even a single chromosome is not properly attached to the mitotic spindle (5, 7) .
The mitotic checkpoint complex contains the anaphasepromoting complex/cyclosome activator cdc20, as well as mitotic checkpoint kinases (McKs) such as Mad2 (mitotic arrest deficient-like 1; MAD2L1), BubR1 (budding uninhibited by benzimidazoles 1 homolog ß; BUB1B) and Bub3. The McKs are regarded as effectors of the mitotic checkpoint. Within the McK complex, both Mad2 and Bubr1 directly bind cdc20 (8) . a large number of aneuploid cell lines do not appear to harbor mutations in the known mitotic checkpoint genes. it is thus possible that mitotic checkpoint dysfunction in these cell lines results from altered expression levels of the known checkpoint genes (9) .
at the mitotic checkpoint, the chromosomal passenger complex lies at the top of a cascade that recruits other McKs (10) . The core chromosomal passenger complex is composed of aurKB (aurora kinase B) and three non-enzymatic subunits, incenP, survivin and borealin. The non-enzymatic members of the complex control the targeting enzymatic activity and stability of aurKB (11, 12) . aberrant expression of the McKs or chromosomal passenger protein in mammalian cells leads to aneuploidy. overexpression of Mad2, Bubr1 or aurKB has been observed in human cancer cells (13) (14) (15) , suggesting that this aberrant expression plays an important role in cancer initiation and progression. We hypothesized that mitotic checkpoint dysfunction is associated with gastric cancer. in the present study, Mad2, BubR1 and AURKB mrna expression was investigated in gastric cancer using real-time quantitative reverse transcription- (Table i) . Patients did not undergo pre-operative chemotherapy or radiotherapy, nor adjuvant chemotherapy following surgical resection. Stage iV patients received s-1-based systemic chemotherapy without any radiotherapy. all patients underwent a follow-up examination, with a median follow-up time at analysis of 19 months. during this period, there were 23 cases of recurrence, and 27 patients succumbed to the disease. immediately after surgery, a small piece of gastric cancer tissue and matched adjacent normal mucosa (taken from the borders of the surgical specimen) were separately placed directly in rna stabilization reagent (rnalater, Qiagen, Valencia, CA) and stored at -80˚C until further analysis.
The study was approved by the institutional review Board of the Tokyo Medical and dental university. Written informed consent was obtained from all patients.
RNA extraction and cDNA synthesis. Total rna for each sample was extracted using the rneasy Mini Kit (Qiagen) according to the manufacturer's protocol. The concentration of total rna was determined by absorption measurements at 260 and 280 nm using a uV spectrophotometer (Beckman coulter, fullerton, ca). for cdna synthesis, 10 µg of total rna was reverse-transcribed into cdna samples using the High capacity cdna reverse Transcription Kit (applied Biosystems, foster city, ca) according to the manufacturer's protocol.
Real-time quantitative RT-PCR. expression levels of Mad2, BubR1 and AURKB, as well as of ß-actin as the endogenous control, were determined by real-time quantitative Pcr using the 7300 real-Time Pcr System (applied Biosystems). TaqMan gene expression assays were purchased from applied Bioystems (Mad2, Hs01554515_g1; BubR1, Hs01084828_m1; AURKB, Hs00177782_m1; ß-actin, Hs99999903_m1). The Pcr reaction was carried out using TaqMan universal Pcr Master Mix (applied Biosystems) with 1 µl of cdna in a 24-µl final reaction volume. Thermal cycling conditions were as follows: 50˚C for 2 min, 95˚C for 10 min, 40 cycles of 15-sec denaturation at 95˚C, and 1 min of annealing at 60˚C. cDNA synthesized by HcT15 was used as the calibrator. each sample was run in duplicate for both the target and endogenous genes. The amount of Mad2, BubR1 and AURKB (target) normalized to the endogenous control and relative to the calibrator was determined by the comparative ct method for relative quantification (∆∆Ct method) (16) using Relative Quantification Study Software (7300 Sequence detection System version 1.4, applied Biosystems).
Statistical analysis. The receiver-operating characteristic (roc) curve was used to determine the cutoff value of each mRNA, as previously reported (17, 18) . Briefly, the ROC curve was constructed by plotting all possible sensitivity/1-specificity pairs resulting from continuously elevating the cutoff values. The optimal cutoff point gave the best combination of specificity and sensitivity according to the ROC curve. This cutoff value was determined using the youden index (18) , which is commonly used to measure overall diagnostic effectiveness. The roc curve can be used to distinguish gastric cancer from normal controls.
differences between groups were evaluated using the Wilcoxon signed-rank test and the ¯2 test. correlation analysis was performed using Spearman's rank correlation. overall survival curves and relapse-free survival curves were plotted according to the Kaplan-Meier method and measured from the day of surgery, with the log-rank test applied for comparisons. Prognostic factors were examined by univariate and multivariate analyses based on cox's proportional hazards model. Differences were considered significant at p<0.05. All analyses were performed with the statistical software package Stat View (version 5.0) (abacus concepts, Berkeley, ca).
Results

Expression of Mad2, BubR1 and AURKB in gastric cancer and determination of cutoff values. Mad2, BubR1
and AURKB mrna expression levels in cancer tissue and normal tissue were assayed by real-time rT-Pcr, and were found to be significantly higher in cancer tissue compared to normal tissue (p<0.001, p<0.001 and p<0.001, respectively; Fig. 1 ). There was significant correlation between Mad2 and BubR1, Mad2 and AURKB, and BubR1 and AURKB (Ú=0.424, p<0.001; Ú=0.375, p<0.001; Ú=0.619, p<0.001; respectively; Fig. 2) .
The cutoff values for Mad2, BubR1 and AURKB were calculated using the roc curve as 0.038, 0.244 and 0.170, respectively. Patients with cancer tissue values below the cutoff were considered to be in the low expression group, whereas those with cancer tissue values above the cutoff were placed in the high expression group. High Mad2 expression was noted in 65% (65/100), high Bubr1 expression in 66% (66/100), and high aurKB expression in 56% (56/100) of patient tissue samples (Table i) .
Correlation between clinicopathological factors and Mad2, BubR1 and AURKB mRNA expression. Table i shows the clinicopathological data and Mad2, BubR1 and AURKB mrna expression levels in the cancer tissue. Mad2 was significantly associated with lymph node metastasis (p=0.040). BubR1 was significantly associated with depth of invasion, distant metastasis, stage classification, lymphatic invasion, and histological type (p=0.007, 0.011, 0.001, 0.007 and 0.003, respectively). AURKB was significantly associated with lymph Table i . comparison of Mad2, BubR1 and AURKB mrna expression and clinicopathological parameters.
Mad2
BubR1 Fig. 3a ; p=0.020, Fig. 3b, respectively) . No other factors were significantly associated with RFS and OS. among the stage ii and iii patients (n=53), there were 14 cases (26%) of recurrence, and 13 patients (25%) succumbed to the disease. BubR1 mrna expression was not associated with patient survival.
Survival was also analyzed in relation to the combination of BubR1 and AURKB mrna expression, since aurKB is a regulator of Bubr1 during chromosome alignment at the metaphase (19) . Four different subgroups were identified: low BubR1/low AURKB (n=10), high BubR1/low AURKB (n=14), low BubR1/high AURKB (n=6), and high Bubr1/high AURKB (n=23). Patients with high expression of BubR1 and/ or AURKB had a more favorable outcome, though without significant differences between the three groups (data not shown). consequently, these three groups were considered a single group. High BubR1 and/or high AURKB expression was associated with significantly increased OS (p=0.012; Fig. 3c ), but not rfS. Univariate and multivariate analysis of survival. univariate and multivariate analyses of factors related to oS were performed for all patients (n=100). The same analyses of factors related to rfS were performed for patients who underwent r0 surgery (n=88). univariate analysis for rfS revealed that depth of invasion, stage classification, histological type and BubR1 mRNA expression level were significantly associated with patient survival (p=0.001, <0.001, 0.049 and 0.038, respectively; Table II ). According to the multivariate analysis, depth of invasion was the only independent prognostic factor for RFS (p=0.027; Table II ). In terms of OS using univariate analysis, depth of invasion, lymph node metastasis, stage classification and BubR1 mrna expression level were significantly associated with patient survival (p=0.002, 0.015, 0.009 and 0.025, respectively; Table III ). In the multivariate analysis, lymph node metastasis was the only independent prognostic factor for OS (p=0.037; Table III ). The expression level of BubR1 mRNA was a significant predictor according to univariate, but not multivariate, analysis. in stage ii and iii patients (n=22, n=31, respectively), according to univariate and multivariate analyses, the combination of BubR1 and AURKB mrna expression levels was an independent and significant prognostic factor for OS (p=0.024; multivariate analysis, Table iV), but not for rfS.
Discussion
We revealed a significant correlation between Mad2, BubR1 and AURKB mrna expression levels and clinicopathological factors in gastric cancer. in addition, the combination of BubR1 and AURKB mRNA expression was identified as an independent prognostic factor. These findings suggest that Mad2, BubR1 and AURKB play a crucial role in gastric cancer progression.
aneuploidy is commonly observed in the majority of human solid tumors (20,21), including gastric cancer (6) . While complete loss of the mitotic checkpoint is lethal in vertebrates, a weakened mitotic checkpoint is frequently noted in cancer cells. it has been speculated that a weakened mitotic checkpoint contributes to aneuploidy and tumorigenesis without loss of viability (22) . aneuploid human cancers frequently exhibit altered expression of the mitotic kinases (including Mad2, Bubr1 and aurKB) (21) . often, this takes the form of overexpression (20,23). The mitotic kinases must be tightly regulated, as both their reduced amounts and overproduction induce aneuploidy (5, 14) . although Mad2, BubR1 and AURKB have not been established as oncogenes by the standard criteria, overexpression of Mad2 in transgenic mice leads to a wide variety of neoplasias, and exogenous overexpression of aurKB in chinese hamster embryo cells leads to chromosomal instability (24, 25) . in the present study, we detected overexpression of Mad2, BubR1 and AURKB mrna in gastric cancer. Mad2, BubR1 and AURKB mrna expression levels were positively correlated with each other, suggesting that Mad2, Bubr1 and aurKB are controlled by a common linking factor. overexpression of Mad2, BubR1 and AURKB was more frequently observed during the earlier stages of cancer development compared to advanced stages. These results suggest that overexpression of Mad2, BubR1 or AURKB contributes to the initiation of tumorigenesis and, subsequently, the inhibition of gastric cancer progression. in a recent study, centromere protein E haplo-insufficient mice (which had a weakened mitotic checkpoint) exhibited increased frequency of spontaneous lymphomas and lung tumors. unexpectedly, treatment with chemical tumor inducers inhibited tumorigenesis in these mice (26) . These findings indicate that moderate levels of genetic instability promote cell growth and tumorigenesis, whereas high levels result in cell death and tumor suppression. The most surprising finding was the identification of a previously unsuspected role for aneuploidy in suppressing tumor growth (27) . it is now widely accepted that gastric cancer develops through the accumulation of genetic alterations (28) that consist of abnormal chromosome numbers (e.g., aneuploidy, polyploidy) and structural changes (e.g., translocations, mutations) (29) . aneuploidy is a very early event in the progression of gastric cancer. The molecular mechanism that initiates and drives aneuploidy has not been identified. Several possibilities exist, such as defective sister chromatid cohesion or an abnormal (30) . it is highly probable that gastric cancer progression is more affected by BubR1 than by Mad2. in contrast to our study, overexpression of Bubr1 was reported to decrease patient survival in colorectal and bladder carcinoma (31, 32) . further research is necessary to clarify the true role and determine the effects of Bubr1 in gastric cancer.
univariate analysis Multivariate analysis -------------------------------------------------------------------------------------------------------------------------------------------------------
in the present study, high BubR1 mrna expression was correlated with a low risk of relapse and improved survival in all patients, with the exception of patients with stage ii and iii disease. Since Bubr1 is regulated by aurKB during chromosome alignment (33), we hypothesized that the combination of BubR1 and AURKB expression might be of prognostic importance in gastric cancer. indeed, stage ii and iii patients with high BubR1 and/or high AURKB had an improved oS, and the combination of BubR1 and AURKB was the only independent and significant prognostic factor for OS in these patients. These findings suggest that overexpression of BubR1 and/or AURKB plays a crucial role in suppressing cancer growth.
in conclusion, we demonstrated the prognostic value of the combined assessment of BubR1 and AURKB mrna expression in gastric cancer patients. High BubR1 and/or high AURKB expression identifies a highly favorable risk group among gastric cancer patients. further studies are clearly required to verify these findings, establishing Mad2, BubR1 and aurKB as prognostic markers in gastric cancer, and functional analysis to clarify their role as tumor suppressors is needed. 
